Currently, one of the stated goals of Dr. St. Amand's not-for-profit Fibromyalgia Treatment Center is to provide supporting research for the GUAIFENESIN Protocol.
A publication of a research has been presented at the Paris international meeting of rheumatology in June 2008 : "High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia", Experimental Biology and Medicine (Maywood) June 5, 2008,. PMID: 18535166, by Zhang Z, Cherryholmes G, Mao A, Marek C, Kalos M, St. Amand RP, Shively JE, City of Hope. The research has identified in fibromyalgia abnormal elevations of various cytokines and chemokines. In patients taking GUAIFENESIN, many of them, for example, tumor necrosis factor alpha (TNF alpha) and Interferon Gamma, arenormalized. Another cytokine abnormality has been found since that paper was published.
Similar cytokine profiles found in family members of fibromyalgics support the idea that FMS has a genetic component.
Another publication reports three genetic mutations in 40% of fibromyalgics patients studied.
On October, 2009, Dr. St. Amand wrote to me: "We have 600 frozen specimens of fibromyalgics' AND awaiting further investigation on gene mutations. Another study, with the Hitachi Corporation Medical Division, is looking more directly into the energy of certain cells… I have greaterhope that this study will ultimately provide a blood test for fibromyalgia. Obviously, our entire thrust now besides getting patients well, is to get such a test that would be available to all laboratories."
"We cannot double-blind a study since, in the USA, GUAIFENESIN is now an over-the-counter drug", wrote to me Dr. St. Amand, on August, 2008.
Dr. St. Amand's work on fibromyalgia and GUAIFENESIN was rewarded by his promotion from assistant to associate Professor in 2004 at UCLA.